SEC Form 4 filed by Vice Chairman Holubiak Myron Z
$CTXR
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
| Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | |||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
Citius Pharmaceuticals, Inc. [ CTXR ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
|
3. Date of Earliest Transaction
(Month/Day/Year) 08/08/2025 | ||||||||||||||||||||||||||
|
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Common Stock | 79,690 | D | ||||||||
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Warrant to Purchase Common Stock(1) | $28.75 | 08/08/2025 | D(1) | 31,373 | (1) | 08/14/2025 | Common Stock | 31,373 | (1) | 0 | D | ||||
| Warrant to Purchase Common Stock(1) | $28.75 | 08/08/2025 | A(1) | 31,373 | (1) | 08/14/2026 | Common Stock | 31,373 | (1) | 31,373 | D | ||||
| Warrant to Purchase Common Stock(2) | $19.25 | 08/08/2025 | D(2) | 22,344 | (2) | 09/27/2025 | Common Stock | 22,344 | (2) | 0 | D | ||||
| Warrant to Purchase Common Stock(4) | $19.25 | 08/08/2025 | A(2) | 22,344 | (2) | 09/27/2026 | Common Stock | 22,344 | (2) | 22,344 | D | ||||
| Stock Option (Right to Purchase Common Stock) | $9.5 | (3) | 11/07/2034 | Common Stock | 14,000 | 14,000 | D | ||||||||
| Stock Option (Right to Buy) | $9.5 | (4) | 11/07/2034 | Common Stock | 3,000 | 3,000 | I | See footnote(4) | |||||||
| Stock Option (Right to Purchase Common Stock) | $17.5 | (5) | 10/10/2033 | Common Stock | 16,000 | 16,000 | D | ||||||||
| Stock Option (Right to Purchase Common Stock) | $31.25 | (6) | 10/04/2032 | Common Stock | 16,000 | 16,000 | D | ||||||||
| Stock Option (Right to Purchase Common Stock) | $51 | (7) | 10/11/2031 | Common Stock | 26,000 | 26,000 | D | ||||||||
| Stock Option (Right to Purchase Common Stock) | $51 | (4) | 10/11/2031 | Common Stock | 600 | 600 | I | See footnote(4) | |||||||
| Stock Option (Right to Purchase Common Stock) | $50 | (7) | 07/22/2031 | Common Stock | 12,000 | 12,000 | D | ||||||||
| Stock Option (Right to Purchase Common Stock) | $50 | (4) | 07/22/2031 | Common Stock | 400 | 400 | I | See footnote(4) | |||||||
| Stock Option (Right to Purchase Common Stock) | $25.25 | (7) | 10/06/2030 | Common Stock | 8,000 | 8,000 | D | ||||||||
| Stock Option (Right to Purchase Common Stock) | $16.75 | (7) | 10/08/2029 | Common Stock | 7,000 | 7,000 | D | ||||||||
| Stock Option (Right to Purchase Common Stock) | $40.5 | (7) | 09/04/2028 | Common Stock | 6,000 | 6,000 | D | ||||||||
| Stock Option (Right to Purchase Common Stock) | $86.25 | (7) | 09/13/2027 | Common Stock | 1,600 | 1,600 | D | ||||||||
| Stock Option (Right to Purchase Common Stock) | $202.5 | (7) | 10/01/2025 | Common Stock | 1,067 | 1,067 | D | ||||||||
| Explanation of Responses: |
| 1. The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. |
| 2. The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. |
| 3. The options were granted on November 7, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. |
| 4. The options are held by the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares. |
| 5. The options were granted on October 10, 2023. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. |
| 6. The options were granted on October 4, 2022. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. |
| 7. The options are vested in full and exercisable immediately. |
| Remarks: |
| All share amounts reflect the 1-for-25 reverse stock split effective November 22, 2024. |
| /s/ Alexander M. Donaldson, by power of attorney | 08/12/2025 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||